RGS14 and metabolic dysfunction-associated steatotic liver disease: In nonalcoholic fatty liver disease (NAFLD), the RGS14-Giα1/3 interaction enhances adenylate cyclase activity, increasing cAMP levels and stimulating AMPK signaling (Wang et al. 2024).